Literature DB >> 17437511

Characteristics of cardiac and vascular structure and function in Prader-Willi syndrome.

Sanjay Patel1, Jason A Harmer, Georgina Loughnan, Michael R Skilton, Katharine Steinbeck, David S Celermajer.   

Abstract

OBJECTIVE: Prader-Willi syndrome (PWS) is a genetic obesity syndrome characterized by hyperphagia, behavioural disturbance and intellectual disability. PWS appears to be associated with a high incidence of sudden death, suspected to be cardiopulmonary in origin. We therefore sought to provide an assessment of cardiac and vascular structure and function in patients with PWS. PATIENTS: Nine patients with genetically confirmed PWS, mean age 28 years, body mass index (BMI) 42 kg/m2, were compared with nine age- and gender-matched lean controls. MEASUREMENTS: Lipid parameters, high-sensitivity C-reactive protein (hs-CRP) and fasting glucose and insulin were measured. To assess cardiac structure and function, a resting electrocardiogram (ECG), exercise stress test, 24-h continuous ECG monitoring, and echocardiogram were obtained. Patients and control subjects also underwent comprehensive noninvasive vascular assessment, including venous-occlusion forearm plethysmography, brachial artery flow-mediated dilatation (FMD), radial artery tonometry and carotid intima-media thickness (IMT) measurements.
RESULTS: All patients with PWS had significantly elevated hs-CRP (> 3.0 mg/l) (mean 11.5 mg/l, median 11.47, interquartile range: 4.48-15.8 mg/l), compared with controls (P < 0.001). Five of nine patients with PWS had subnormal exercise capacity (< 4 mets on exercise stress testing). Twenty-four-hour ECG monitoring revealed prolonged sinus pauses in one patient, up to 4.8 s, requiring pacemaker insertion. Microvascular function as assessed by peak hyperaemic flow response was decreased in PWS (6.1 +/- 1.0 times baseline flow vs. controls 13.5 +/- 1.6 times baseline flow, P = 0.01). Other measures were similar between PWS and controls.
CONCLUSIONS: This group of PWS patients had significantly raised levels of the inflammatory marker hs-CRP and evidence of microcirculatory dysfunction, both of which are associated with coronary artery disease and early sudden death. The sinus node dysfunction may in itself be a risk factor for sudden cardiac death.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17437511     DOI: 10.1111/j.1365-2265.2007.02808.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  7 in total

1.  Effects of MetAP2 inhibition on hyperphagia and body weight in Prader-Willi syndrome: A randomized, double-blind, placebo-controlled trial.

Authors:  Shawn E McCandless; Jack A Yanovski; Jennifer Miller; Cary Fu; Lynne M Bird; Parisa Salehi; Christine L Chan; Diane Stafford; M Jennifer Abuzzahab; David Viskochil; Sarah E Barlow; Moris Angulo; Susan E Myers; Barbara Y Whitman; Dennis Styne; Elizabeth Roof; Elisabeth M Dykens; Ann O Scheimann; Jaret Malloy; Dongliang Zhuang; Kristin Taylor; Thomas E Hughes; Dennis D Kim; Merlin G Butler
Journal:  Diabetes Obes Metab       Date:  2017-07-13       Impact factor: 6.577

2.  Growth hormone therapy improves exercise capacity in adult patients with Prader-Willi syndrome.

Authors:  L A Gondoni; L Vismara; P Marzullo; R Vettor; A Liuzzi; G Grugni
Journal:  J Endocrinol Invest       Date:  2008-09       Impact factor: 4.256

3.  Scoliosis in patients with Prader Willi Syndrome - comparisons of conservative and surgical treatment.

Authors:  Hans-Rudolf Weiss; Deborah Goodall
Journal:  Scoliosis       Date:  2009-05-06

4.  Baroreflex Dysfunction in Prader Willi Syndrome.

Authors:  Manpreet Kaur; Shival Srivastav; Ashok Kumar Jaryal; Kishore Kumar Deepak
Journal:  J Clin Diagn Res       Date:  2016-03-01

5.  Altered inflammation, paraoxonase-1 activity and HDL physicochemical properties in obese humans with and without Prader-Willi syndrome.

Authors:  Gianna Ferretti; Tiziana Bacchetti; Simona Masciangelo; Graziano Grugni; Virginia Bicchiega
Journal:  Dis Model Mech       Date:  2012-07-19       Impact factor: 5.758

6.  Effects of adiposity and Prader-Willi Syndrome on postexercise heart rate recovery.

Authors:  Diobel M Castner; Daniela A Rubin; Daniel A Judelson; Andrea M Haqq
Journal:  J Obes       Date:  2013-05-22

Review 7.  Growth hormone therapy for Prader-willi syndrome: challenges and solutions.

Authors:  Graziano Grugni; Alessandro Sartorio; Antonino Crinò
Journal:  Ther Clin Risk Manag       Date:  2016-06-02       Impact factor: 2.423

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.